You are here

Article Text

Article menu
Download PDFPDF
Preface
Advances in targeted therapies XIII
  1. FC Breedveld1,
  2. JR Kalden2,
  3. JS Smolen3
  1. 1Department of Rheumatology C4-r, University Hospital Leiden, Leiden, Netherlands
  2. 2Institute for Clinical Immunology and Rheumatology, Erlangen, Germany
  3. 3Department of Rheumatology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Professor FC Breedveld, Department of Rheumatology C4-r, University Hospital Leiden, Leiden 2300 RC, Netherlands; f.c.breedveld{at}lumc.nl

https://doi.org/10.1136/annrheumdis-2011-201013

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations at the XIIIth International Symposium on Advances in Targeted Therapies, which was held from 6 to 9 April 2011. These presentations represent the state of the art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF) and other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF or other molecules or cellular mechanisms is also presented.

    We are grateful to Drs Crofford, Feldmann, …

    View Full Text

    Footnotes

    • Funding The following companies provided unrestricted educational grants for the organisation of this conference: Abbott, Amgen, Bristol-Myers Squibb, Mitsubishi Tanabe, Pfizer, Roche, Savient Pharmaceuticals and UCB. The pharmaceutical industry had no part in the decisions about the specific programme and, with the exception of a few observers, participants were selected and invited solely by the organising committee.

    • Competing interests Several members of the advisory board and the members of the organising committee obtained experience in the use of biological compounds during their participation in clinical studies on these agents (for which the costs were defrayed by industry).

    • Provenance and peer review Commissioned; internally peer reviewed.